Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of fractionated Hyper-CVAD for relapsed or refractory adult acute lymphoblastic leukemia
2007-003884-30Phase 2Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Mar 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate and 2 more in acute lymphoblastic leukemia (ALL), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoints: Safety and tolerability and Anti-leukemic activity. Started Mar 2008; status: completed.
02
Drugs
cyclophosphamidevincristinedoxorubicindexamethasonemethotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2007-003884-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003884-30.